Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | Director | January 02, 2026 | January 06, 2026 |
| OTONOMY, INC.OTIC · Entity 116495 | Director | June 21, 2022 | June 23, 2022 |
| TALPHERA, INC.TLPH · Entity 7102 | Director | June 22, 2026 | June 24, 2026 |
| aTYR PHARMA INCATYR · Entity 7233 | Chief Financial Officer | February 03, 2026 | February 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.34 · Expires 2036-01-01 | Direct | 24,400 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 24,400 · Balance 24,400 F1: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2: This stock option becomes fully exercisable on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.
F2: This stock option becomes fully exercisable on the first anniversary of the grant date.
OTONOMY, INC.
Report date June 21, 2022 · Filed June 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 · Expires 2032-06-20 | Direct | 27,500 |
Reported balance
After 2022-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-21 · Grant · Acquired 27,500 · Balance 27,500 F1: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date.
TALPHERA, INC.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,647 |
Reported balance
After 2026-06-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 5,100 · Balance 13,647 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2036-06-21 | Direct | 30,700 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Grant · Acquired 30,700 · Balance 30,700 F3: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: 100% of the restricted stock units shall vest on the first anniversary of the grant date, subject to Reporting Person's continuous service to the Company.
F3: 100% of the shares subject to the option shall vest on the one-year anniversary of the grant date, subject to the Reporting Person's continuous service to the Company.
aTYR PHARMA INC
Report date February 03, 2026 · Filed February 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,296 |
Ending reported balance
After 2026-02-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-03 · Exercise / conversion · Acquired 3,750 · Balance 38,854 F1: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022. F2: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2026-02-04 · Sale · Disposed 1,558 · Balance 37,296 F3: Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-03 · Exercise / conversion · Disposed 3,750 · Balance 0 F2: Restricted stock units convert into common stock on a one-for-one basis. F4: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
F2: Restricted stock units convert into common stock on a one-for-one basis.
F3: Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022.
F4: The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 20, 2018 Filed Sep 21, 2018 20:38 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 38,000 | $0.84 | $31,737.60 |
DisclosureSEC source: 0001209191-18-051897 · doc4.xml · nonDerivative · entry 2 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F2 · price: Represents weighted average price for the shares. The shares were purchased at price ranging from $0.8229 to $0.8480 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 19, 2018 Filed Sep 21, 2018 20:38 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 26,000 | $0.81 | $21,117.20 |
DisclosureSEC source: 0001209191-18-051897 · doc4.xml · nonDerivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 F1 · price: Represents weighted average price for the shares. The shares were purchased at price ranging from $0.7989 to $0.8184 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| September 14, 2018 Filed Sep 18, 2018 22:12 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 26,000 | $0.73 | $19,055.40 |
DisclosureSEC source: 0001209191-18-051547 · doc4.xml · nonDerivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 F1 · price: Represents weighted average price for the shares. The shares were purchased at price ranging from $0.729 to $0.736 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 20:56 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-18-044758 · doc4.xml · derivative · entry 1 Broadfoot Jill Marie · CIK 0001305178 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-07-30 F1 · derivative.exercise_date: 1/4 of the shares subject to this option shall vest and become exercisable on July 30, 2018, and the remainder shall thereafter vest and become exercisable in 36 equal monthly installments, such that this option will be fully exercisable on July 30, 2022. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.